Literature DB >> 12509667

Combination antipsychotic therapy in clinical practice.

Andre Tapp1, Amanda Ernst Wood, Lori Secrest, Jaime Erdmann, Lindy Cubberley, Nael Kilzieh.   

Abstract

OBJECTIVE: Surveys have shown that antipsychotic drug combinations are frequently prescribed, yet few clinical studies have examined this practice. Experts have generally recommended antipsychotic combinations, especially those combining an atypical and a conventional antipsychotic, as a measure of last resort. A survey of prescribers was conducted to examine why combination antipsychotic therapy is being used in outpatient clinical practice.
METHODS: Antipsychotic prescribing practices in the Department of Veterans Affairs Puget Sound Health System were reviewed for a six-month period during 1998-1999. Data on the use of atypical and conventional antipsychotics in combination were collected.
RESULTS: A total of 1,794 patients received prescriptions for at least one antipsychotic medication during the study period, of which 715 (40 percent) received an atypical agent. Ninety-three patients (13 percent) who were treated with an atypical antipsychotic received a prescription for combination antipsychotic therapy for at least 30 days. In cases in which both a conventional and an atypical agent were prescribed, the primary reason given for adding a conventional antipsychotic medication was to treat persistent positive symptoms. The primary reason an atypical agent was added to a conventional agent was to switch medications to the atypical agent; however, a significant number of patients became "stuck" on the combination.
CONCLUSIONS: The results of this study support previous reports of the frequent use of combination antipsychotic therapy in clinical practice. Prospective controlled trials are needed to substantiate perceptions that combination antipsychotic therapy is clinically beneficial and to provide guidelines on when and for whom antipsychotic polypharmacy should be considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509667     DOI: 10.1176/appi.ps.54.1.55

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  41 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 4.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 5.  Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.

Authors:  Hiroyoshi Takeuchi; Navot Kantor; Hiroyuki Uchida; Takefumi Suzuki; Gary Remington
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 6.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

7.  Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

Authors:  Britta Galling; Alexandra Roldán; Katsuhiko Hagi; Liz Rietschel; Frozan Walyzada; Wei Zheng; Xiao-Lan Cao; Yu-Tao Xiang; Mathias Zink; John M Kane; Jimmi Nielsen; Stefan Leucht; Christoph U Correll
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

Review 8.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

10.  Description of long-term polypharmacy among schizophrenia outpatients.

Authors:  Jaana T Suokas; Jaana M Suvisaari; Jari Haukka; Pasi Korhonen; Jari Tiihonen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-09-25       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.